


**Appendix 1 Detailed search strategy for all databases**

**PubMed:** (((("2004/01/01"[Date - Publication] : "2023/12/31"[Date - Publication])) AND ((subcutaneous) AND ((hypertrophic cardiomyopathy) OR (hypertrophic cardiomyopathy[MeSH Terms]))))



**Embase:** 'subcutaneous' AND ('hypertrophic cardiomyopathy'/exp OR 'hypertrophic cardiomyopathy') AND [2004-2023]/py

**Scopus:** (TITLE-ABS-KEY("subcutaneous" AND "hypertrophic cardiomyopathy") AND PUBYEAR > 2003 AND PUBYEAR < 2024)

**Cochrane:** : 'subcutaneous' AND ('hypertrophic cardiomyopathy'/exp OR 'hypertrophic cardiomyopathy') AND [2004-2023]/



**Figure S1** Publication bias assessment through funnel plot for appropriate shocks (A), inappropriate shocks (B), and device-related complications (C). SE, standard error; OR, odds ratio.



**Figure S2** Leave-one-out cross-validation found no difference in AS, IAS, and DRC; however, we observed a substantial reduction in heterogeneity when excluding Lambiase from AS. AS, appropriate shocks; IAS, inappropriate shocks; DRC, device-related complication; CI, confidence interval; S-ICD, subcutaneous implanted cardioverter-defibrillator; TV-ICD, transvenous implanted cardioverter-defibrillator.

Study	Bias due to confounding	Bias in the selection of participants	Bias in the classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in the measurement of outcomes	Bias in the selection of the reported result	The overall risk of bias judgement
Boungiorno 2022	Low	Serious	Moderate	Low	Low	Moderate	Low	Serious
Francia, 2023	Moderate	Low	Serious	Low	Low	Low	Low	Moderate
Jankelson, 2022	Low	Low	Low	Low	Low	Low	Low	Low
Klein, 2017	Moderate	Low	Moderate	Moderate	Low	Moderate	Low	Moderate
Lambiase, 2016	Critical	Low	Moderate	Moderate	Low	Low	Low	Critical
Steiger, 2019	Moderate	Low	Low	Low	Moderate	Low	Low	Moderate
Timmers, 2017	Moderate	Serious	Low	Low	Moderate	Low	Low	Serious

**Figure S3** Critical appraisal of individual studies according to the Cochrane Collaboration's tool for assessing risk of bias in non randomized trial (ROBINS-I).